Holen Sie sich die Stockscreener-App
18.00
1.67%
0.295
Schlusskurs vom Vortag:
$17.70
Offen:
$17.81
24-Stunden-Volumen:
467.50K
Relative Volume:
0.37
Marktkapitalisierung:
$3.08B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-382.71M
KGV:
-6.8683
EPS:
-2.62
Netto-Cashflow:
$-325.64M
1W Leistung:
+2.89%
1M Leistung:
+13.89%
6M Leistung:
-22.54%
1J Leistung:
-35.73%
1-Tages-Spanne:
$17.77
$18.09
1-Wochen-Bereich:
$17.41
$18.67
52-Wochen-Spanne:
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
18.00 | 3.18B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.88 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.14 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.48 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.71 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.50 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-03-03 | Eingeleitet | Jefferies | Hold |
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
What analysts say about Immunovant Inc. stockFree Stock Market Mentorship - jammulinksnews.com
What drives Immunovant Inc. stock priceExceptional profit margins - jammulinksnews.com
Immunovant Inc. Stock Analysis and ForecastUnstoppable trading performance - jammulinksnews.com
Teacher Retirement System of Texas Buys 2,919 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
why immunovant inc. stock attracts strong analyst attentionFree Access to Community - Newser
Is Immunovant Inc. a good long term investmentDynamic profit opportunities - jammulinksnews.com
September 19th Options Now Available For Immunovant (IMVT) - Nasdaq
(IMVT) Trading Advice - news.stocktradersdaily.com
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy - Yahoo Finance
Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating - MSN
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High? - Yahoo Finance
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
What makes Immunovant Inc. stock price move sharplyShort Squeeze Radar - Newser
Why Immunovant Inc. stock attracts strong analyst attentionDaily Volume Leaders - Newser
How Immunovant Inc. stock performs during market volatilityFree Trading Strategy Suggestions - Newser
Principal Financial Group Inc. Sells 31,255 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
The Goldman Sachs Group Upgrades Immunovant (NASDAQ:IMVT) to Hold - Defense World
Immunovant (IMVT) chief technology officer Stout sells $26k in stock - Investing.com Australia
Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView
Immunovant Shares Soar 3.60% on Insider Trading Activity - AInvest
Goldman Sachs resumes Immunovant stock coverage with Neutral rating By Investing.com - Investing.com Canada
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World
(IMVT) Technical Data - news.stocktradersdaily.com
How to Take Advantage of moves in (IMVT) - news.stocktradersdaily.com
Immunovant (NASDAQ:IMVT) Stock Updated Nasdaq Composite - Kalkine Media
Zacks Research Comments on Immunovant FY2028 Earnings - Defense World
Rhumbline Advisers Has $1.43 Million Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
GAMMA Investing LLC Buys 5,229 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Learn to Evaluate (IMVT) using the Charts - news.stocktradersdaily.com
Immunovant, Inc. (NASDAQ:IMVT) Receives $38.33 Consensus Target Price from Brokerages - Defense World
Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade) - Seeking Alpha
Cantor Fitzgerald Forecasts Immunovant FY2027 Earnings - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Wellington Management Group LLP - Defense World
Two Sigma Advisers LP Buys New Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Ameriprise Financial Inc. Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Dexcom (DXCM) and Immunovant (IMVT) - The Globe and Mail
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com
Leerink Partnrs Estimates Immunovant FY2030 Earnings - Defense World
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus - MSN
Immunovant price target lowered to $35 from $51 at H.C. Wainwright - TipRanks
Immunovant’s Promising Future: Buy Rating Backed by Strategic Advancements and Strong Cash Position - TipRanks
Immunovant Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunovant Inc-Aktie (IMVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Stout Jay S | Chief Technology Officer |
Jul 09 '25 |
Sale |
17.24 |
1,519 |
26,188 |
207,724 |
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):